Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big pharma is set to keep signing bigger deals in 2024

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 14, 2024 2:58pm

142 Views

Post# 35933322

RE:RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

With BMS acquiring a Phase 3 small molecule company Mirati for US$4.8 Billion n January 2024, whose product portfolio doesn't have the same level of market exclusivity as would a Phase 3 biologics company that has been given an extra 4 years of marketing protection under the Inflation Reduction Act (IRA) passed in 2022, ONCY's biologics platform that fits into the further favored orphan/rare drug space, should have an acquisition valuation that is far in excess of US$5+ Billion.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages